ESMO23 BCa highlights

ESMO2023 is coming up from 20th-24th October in Madrid this year. Here are the BCa highlights our editorial board selected.

Metastatic Urothelial carcinoma

• Phase 3 THOR Study: Results of Erdafitinib vs Pembrolizumab in Pretreated Patients With Advanced or Metastatic Urothelial Cancer With Select Fibroblast Growth Factor Receptor Alterations – Arlene O. Siefker-Radtke
• Erdafitinib  vs Chemotherapy in Patients With Advanced or Metastatic Urothelial Cancer With Select FGFR Alterations: Subgroups From the Phase 3 THOR Study – Yohann Loriot
• Nivolumab plus gemcitabine-cisplatin versus gemcitabine-cisplatin alone for previously untreated unresectable or metastatic urothelial carcinoma: results from the phase 3 CheckMate 901 trial – Michiel S. Van der Heijden
• ICRA: efficacy of paclitaxel with tremelimumab +/- durvalumab in metastatic urothelial carcinoma after progression on platinum chemotherapy and anti-PD-(L)1 – Sarah M.H. Einerhand
• EV-302/KEYNOTE-A39: Open-Label, Randomized Phase 3 Study of Enfortumab Vedotin in Combination with Pembrolizumab (EV+P) Vs Chemotherapy (Chemo) in Previously Untreated Locally Advanced Metastatic Urothelial Carcinoma (la/mUC) – Thomas B. Powles

Muscle invasive bladder cancer

• Impact of Positron Emission Tomography Imaging on Staging of Muscle-Invasive Bladder Cancer – Srikala Sridhar
• A phase II study investigating the safety and efficacy of neoadjuvant atezolizumab in non-urothelial, muscle invasive bladder cancer (ABACUS-2) – Bernadett E. Szabados
• Study EV-103 Cohort L: Perioperative treatment w/ enfortumab vedotin monotherapy in cisplatin (cis)-ineligible patients w/ muscle invasive bladder cancer – Srikala Sridhar

Non muscle invasive bladder cancer

• THOR-2 cohort 1: Results of erdafitinib vs intravesical chemotherapy in patients pts) with high-risk non–muscle-invasive bladder cancer with select fibroblast growth factor receptor alterations FGFRALT) who received prior bacillus calmette-guérin treatment – James W. Catto
• First safety and efficacy results of the TAR-210 erdafitinib (erda) intravesical delivery system in patients with non–muscle-invasive bladder cancer with select FGFR alterations – Antoni Vilaseca
• Results From SunRISe-1 in Patients With Bacillus Calmette–Guérin (BCG)-Unresponsive High-Risk Non–Muscle-Invasive Bladder Cancer Receiving TAR-200 Monotherapy – Andrea Necchi